-
1
-
-
84890130134
-
-
World Health Organization. Hepatitis C Fact sheet N°164. Available at Accessed 19 October 2012.
-
World Health Organization. Hepatitis C Fact sheet N°164. 2012 Available at http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed 19 October 2012.
-
(2012)
-
-
-
2
-
-
79958717571
-
The global health burden of hepatitis C virus infection
-
Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31 (Suppl. 2): 1-3.
-
(2011)
Liver Int
, vol.31
, Issue.SUPPL. 2
, pp. 1-3
-
-
Negro, F.1
Alberti, A.2
-
3
-
-
84862929577
-
The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan
-
Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012; 15: S65-71.
-
(2012)
Value Health
, vol.15
-
-
Liu, G.G.1
DiBonaventura, M.2
Yuan, Y.3
-
4
-
-
79959722134
-
All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population
-
El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53: 150-7.
-
(2011)
Clin Infect Dis
, vol.53
, pp. 150-157
-
-
El-Kamary, S.S.1
Jhaveri, R.2
Shardell, M.D.3
-
5
-
-
79954708052
-
Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006
-
Walter SR, Thein HH, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011; 54: 879-86.
-
(2011)
J Hepatol
, vol.54
, pp. 879-886
-
-
Walter, S.R.1
Thein, H.H.2
Amin, J.3
-
6
-
-
84856036274
-
Advanced liver disease: what every hepatitis C virus treater should know
-
Sherman KE. Advanced liver disease: what every hepatitis C virus treater should know. Top Antivir Med 2011; 19: 121-5.
-
(2011)
Top Antivir Med
, vol.19
, pp. 121-125
-
-
Sherman, K.E.1
-
7
-
-
81855206319
-
Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C
-
Walter SR, Thein HH, Gidding HF, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 2011; 26: 1757-64.
-
(2011)
J Gastroenterol Hepatol
, vol.26
, pp. 1757-1764
-
-
Walter, S.R.1
Thein, H.H.2
Gidding, H.F.3
-
10
-
-
24944439884
-
National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population
-
Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 2006; 49: 7-17.
-
(2006)
Intervirology
, vol.49
, pp. 7-17
-
-
Yoshizawa, H.1
Tanaka, J.2
Miyakawa, Y.3
-
11
-
-
75349095780
-
Changing trends in hepatitis C infection over the past 50 years in Japan
-
Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39-43.
-
(2010)
Intervirology
, vol.53
, pp. 39-43
-
-
Chung, H.1
Ueda, T.2
Kudo, M.3
-
12
-
-
84860287080
-
Epidemiology of viral hepatitis and hepatocellular carcinoma
-
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
-
(2012)
Gastroenterology
, vol.142
, pp. 1264-1273
-
-
El-Serag, H.B.1
-
13
-
-
84883897873
-
-
Japan Society of Hepatology. Treatment guidelines for chronic hepatitis C.
-
Japan Society of Hepatology. Treatment guidelines for chronic hepatitis C. Hep Research 2013; 43: 1-34.
-
(2013)
Hep Research
, vol.43
, pp. 1-34
-
-
-
14
-
-
83555163652
-
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
-
Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
-
(2012)
J Hepatol
, vol.56
, pp. 78-84
-
-
Kumada, H.1
Toyota, J.2
Okanoue, T.3
-
15
-
-
84890114466
-
Telaprevir in combination with peginterferon alfa 2B and ribavirin therapy for genotype 1 chronic HCV patients: phase 3 study in Japan
-
Abstract No. 1330].
-
Okanoue T, Hayashi N, Tsubouchi H, et al. Telaprevir in combination with peginterferon alfa 2B and ribavirin therapy for genotype 1 chronic HCV patients: phase 3 study in Japan. Hepatology 2011; 54(Suppl. 1): 985A [Abstract No. 1330].
-
(2011)
Hepatology
, vol.54
, Issue.SUPPL. 1
-
-
Okanoue, T.1
Hayashi, N.2
Tsubouchi, H.3
-
16
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
17
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
-
18
-
-
79960328806
-
Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients
-
Ozeki I, Akaike J, Karino Y, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol 2011; 46: 929-37.
-
(2011)
J Gastroenterol
, vol.46
, pp. 929-937
-
-
Ozeki, I.1
Akaike, J.2
Karino, Y.3
-
19
-
-
84890115803
-
-
INCIVEK™ (telaprevir) Highlights of US prescribing information. Accessed 21 February 2012.
-
INCIVEK™ (telaprevir) Highlights of US prescribing information. 2011 Available at http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed 21 February 2012.
-
(2011)
-
-
-
20
-
-
84890118946
-
-
INCIVO™ (telaprevir) Summary of product characteristics. Available at Accessed 19 October 2012.
-
INCIVO™ (telaprevir) Summary of product characteristics. 2011 Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf. Accessed 19 October 2012.
-
(2011)
-
-
-
21
-
-
80054908770
-
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions
-
Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011; 6: 514-26.
-
(2011)
Curr Opin HIV AIDS
, vol.6
, pp. 514-526
-
-
Seden, K.1
Back, D.2
-
22
-
-
77956301340
-
Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)
-
Llinas-Brunet M, Bailey MD, Goudreau N, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem 2010; 53: 6466-76.
-
(2010)
J Med Chem
, vol.53
, pp. 6466-6476
-
-
Llinas-Brunet, M.1
Bailey, M.D.2
Goudreau, N.3
-
23
-
-
79953224799
-
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
-
Manns MP, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-22.
-
(2011)
J Hepatol
, vol.54
, pp. 1114-1122
-
-
Manns, M.P.1
Bourliere, M.2
Benhamou, Y.3
-
24
-
-
78049316315
-
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease
-
White PW, Llinas-Brunet M, Amad M, et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010; 54: 4611-8.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 4611-4618
-
-
White, P.W.1
Llinas-Brunet, M.2
Amad, M.3
-
25
-
-
84878992253
-
Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial
-
Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-54.
-
(2013)
Hepatology
, vol.57
, pp. 2143-2154
-
-
Sulkowski, M.S.1
Asselah, T.2
Lalezari, J.3
-
26
-
-
84878980518
-
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial
-
Sulkowski MS, Bourliere M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-63.
-
(2013)
Hepatology
, vol.57
, pp. 2155-2163
-
-
Sulkowski, M.S.1
Bourliere, M.2
Bronowicki, J.P.3
-
27
-
-
4043117056
-
Design of first-administration studies in healthy man
-
In: O'Grady J, Linet OI (eds), London: MacMillan Press
-
Broom C. Design of first-administration studies in healthy man. In: O'Grady J, Linet OI (eds), Early Phase Drug Evaluation in Man, London: MacMillan Press; 1990. p206-13.
-
(1990)
Early Phase Drug Evaluation in Man
-
-
Broom, C.1
-
28
-
-
80054891773
-
Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335
-
Abstract No. 1236].
-
Sane R, Podila L, Mathur A, et al. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol 2011; 54 (Suppl. 1): S488 [Abstract No. 1236].
-
(2011)
J Hepatol
, vol.54
, Issue.SUPPL. 1
-
-
Sane, R.1
Podila, L.2
Mathur, A.3
-
29
-
-
79960470493
-
SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2A and ribavirin (P.R) in treatment-naive patients with chronic genotype-1 HCV infection
-
Abstract No. 36].
-
Dieterich D, Asselah T, Guyader D, et al. SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2A and ribavirin (P.R) in treatment-naive patients with chronic genotype-1 HCV infection. Hepatology 2011; 54 (Suppl.): 378A [Abstract No. 36].
-
(2011)
Hepatology
, vol.54
, Issue.SUPPL.
-
-
Dieterich, D.1
Asselah, T.2
Guyader, D.3
|